The ORM1 antibody targets Orosomucoid 1 (ORM1), also known as alpha-1-acid glycoprotein (AGP), a major acute-phase protein synthesized primarily in the liver. ORM1 is a member of the immunocalin family, characterized by its ability to bind and transport small hydrophobic molecules, including drugs, hormones, and steroids. It plays a critical role in modulating immune responses, acting as an anti-inflammatory agent by inhibiting neutrophil activation, reducing oxidative stress, and interacting with cell adhesion molecules. ORM1 levels rise significantly during inflammation, infection, or tissue injury, making it a biomarker for acute-phase reactions.
The ORM1 antibody is widely used in research to study its expression, distribution, and function in physiological and pathological contexts. It aids in detecting ORM1 in biological samples (e.g., serum, tissues) via techniques like Western blotting, ELISA, or immunohistochemistry. Studies involving ORM1 antibodies have explored its roles in cancer progression, immune regulation, and drug metabolism, as well as its potential as a diagnostic or prognostic marker in conditions like sepsis, autoimmune diseases, and cancer. Commercial ORM1 antibodies are typically produced in hosts like rabbits or mice, with validation for specificity and sensitivity across applications. Researchers must account for post-translational modifications (e.g., glycosylation) that may affect antibody binding. Overall, ORM1 antibodies are vital tools for unraveling the protein’s multifaceted roles in health and disease.